NCT01122108View on ClinicalTrials.gov

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Healthy
Interventions
DRUG

Cholestyramine

Cholestyramine 12 grams, one time dose

DRUG

Colesevelam HCl

Colesevelam HCl, 4 grams, one time dose

Trial Locations (1)

40213

L-MARC Research Center, Louisville

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Provident Clinical Research

OTHER

collaborator

Daiichi Sankyo

INDUSTRY

lead

Louisville Metabolic and Atherosclerosis Research Center

OTHER